Sichuan Huiyu Pharmaceutical Co. Ltd.SSE: 688553

Announcement on Expected Loss in Performance for 2025

Jan 30, 2026 · Issued by Sichuan Huiyu Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 30, 2026

On 6ix: 6ix.com/news/announcement-on-expected-loss-in-performance-for-2025-150

Announcement on Expected Loss in Performance for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sichuan Huiyu Pharmaceutical Co. Ltd. on 6ix

Earlier from Sichuan Huiyu Pharmaceutical

Announcement on Passive Shareholding Reduction Plan for Shareholders with Over 5% SharesJan 29
Announcement on Estimated Daily Related Party Transactions in 2026Jan 22
Announcement on Voluntary Disclosure of Clinical Study Cooperation with AstraZenecaJan 10
Announcement on Obtaining Drug Registration Certificate for Cimetidine InjectionDec 24, 2025
Announcement on Progress in Participation in Private Equity Fund Investment and Related Party TransactionDec 20, 2025

Later from Sichuan Huiyu Pharmaceutical

Announcement on Result of Passive Shareholding Reduction by Shareholder with Over 5% SharesFeb 11
Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDAFeb 25
Announcement on Voluntary Disclosure of Approval of Etoposide Injection and Fluorouracil Injection by the U.S. FDAFeb 26
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Correction Announcement on Preliminary Earnings Estimate for 2025Mar 2

All Sichuan Huiyu Pharmaceutical news releases

Follow Sichuan Huiyu Pharmaceutical into a list and get an email when it puts out news.

Follow Sichuan Huiyu Pharmaceutical